Published in Volume
117, Issue 10 (October 1, 2007)
J Clin Invest. 2007;117(10):3140–3140.
doi:10.1172/JCI30951C1.
Copyright © 2007, American Society for Clinical Investigation
Corrigendum
Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain
Yi Dai, Shenglan Wang, Makoto Tominaga, Satoshi Yamamoto, Tetsuo Fukuoka, Tomohiro Higashi, Kimiko Kobayashi, Koichi Obata, Hiroki Yamanaka and Koichi Noguchi
Published October 1, 2007
Original citation: J. Clin. Invest.
117:1979-1987 (2007). doi:10.1172/JCI30951.
Citation for this corrigendum: J. Clin. Invest. 117:3140 (2007). doi:10.1172/JCI30951C1.
During the preparation of the manuscript, the doses of ET-18-OCH3, U73122, and GF were incorrectly reported in the legend for Figure 3. The correct sentence appears below.
In some experiments, the bath solution was perfused with either a PLC inhibitor - ET-18-OCH3 (ET; 2 mM) or U73122 (2 mM) - or a PKC inhibitor, GF (0.5 mM or 10 mM) 120 seconds before SL-NH2 reapplication.
The authors regret the error.
